Revision of the General USP Chapter <1010>
Recommendation
Thursday, 29 October 2026 9 .00 - 14.00 h
Practical Approaches for Assessing the Risks of Impurities
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In the Pharmacopoeial Forum 40(3) the In-process-revision of the general USP Chapter <1010> - Analytical Data - Interpretation and Treatment - was announced. This revision was suggested due to the proposals the USP received for this capter.
The part on the use of USP reference substances now also describes more detailed the handling of secondary standards which can be traced back to the USP reference standards.
Further, in the entire document the term "method" was replaced by the term "procedure" as far as the description of analytical testing is concerned. This was done in adapting the document to today's USP terminology.
In addition there will be a new Appendix F in which a new statistical test is described for the evaluation of the equivalence of analytical procedures.
Please see the chapter <1010> - Analytical Data - Interpretation and Treatment for further information.
Source: USP - http://www.usp.org
Related GMP News
21.10.2026EMA Updates Information Page on Bioequivalence Guidelines
21.10.2026BP Publishes new Draft Texts
21.10.2026FDA Identifies Critical Deficiencies in Analytical Testing and CGMP Oversight
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus
07.10.2026Pharmeuropa: Revision Proposed for Chapter 2.5.32 on Coulometric Karl Fischer Water Determination